Docetaxel rechallenge in patients with castration-resistant prostate cancer - A review

European Oncology and Haematology

Volumn 8, Issue 1, 2012, Pages 36-41

  Caffo, Orazio ^a   Pappagallo, Giovanni ^b   Russo, Lucianna Maria ^a   Veccia, Antonello ^a   Galligioni, Enzo ^a  

^a Santa Chiara University Hospital   (Italy)

^b Epidemiology and Clinical Trials Office   (Italy)

Author keywords

Castration resistance; Docetaxel; Predictive factors; Prostate cancer; Rechallenge

Indexed keywords

CABAZITAXEL; CALCITRIOL; CARBOPLATIN; CISPLATIN; DOCETAXEL; ESTRAMUSTINE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PREDNISONE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RECHALLENGE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84864604936     PISSN: 20455275     EISSN: 20455283     Source Type: Journal    
DOI: 10.17925/eoh.2012.08.01.36     Document Type: Review

References (54)

1. Tannock IF, Osoba D, Stockler MR, et al., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 1996;14:1756-64.
2. Kantoff PW, Halabi S, Conaway M, et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study, J Clin Oncol, 1999;17:2506-13.
3. Berry W, Dakhil S, Modiano M, et al., Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer, J Urol, 2002;168:2439-43.
4. Tannock IF, De Wit R, Berry WR, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 2004;351:1502-12.
5. Petrylak DP, Tangen CM, Hussain MH, et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 2004;351:1513-20.
6. Berthold DR, Pond GR, Soban F, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 2008;26:242-5.
7. Michels J, Montemurro T, Murray N, et al., First- and secondline chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?, Cancer, 2006;106:1041-6.
8. Oh WK, Manola J, Babcic V, et al., Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes, Urology, 2006;67:1235-40.
9. Rosenberg JE, Weinberg VK, Kelly WK, et al., Activity of second-line chemotherapy in docetaxel-refractory hormonerefractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone, Cancer, 2007;110:556-63.
10. Berthold DR, Pond GR, De Wit R, et al., Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa, Ann Oncol, 2008;19:1749-53.
11. Sternberg CN, Petrylak DP, Sartor O, et al., Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial, J Clin Oncol, 2009;27:5431-8.
12. Di Lorenzo G, Figg WD, Fossa SD, et al., Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study, Eur Urol, 2008;54:1089-94.
13. Ross RW, Beer TM, Jacobus S, et al., A phase 2 study of carboplatin plus docetaxel in men with metastatic hormonerefractory prostate cancer who are refractory to docetaxel, Cancer, 2008;112:521-6.
14. Caffo O, Sava T, Comploj E, et al., Estramustine plus docetaxel as second-line therapy in patients with hormonerefractory prostate cancer resistant to docetaxel alone, Urol Oncol, 2010;28:152-6.
15. de Bono JS, Oudard S, Ozguroglu M, et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 2010;376:1147-54.
16. de Bono JS, Logothetis CJ, Molina A, et al., Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 2011;364:1995-2005.
17. Harries M, Gore M, Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease, Lancet Oncol, 2002;3:537-45
18. Huisman C, Postmus PE, Giaccone G, et al., Second-line chemotherapy and its evaluation in small cell lung cancer, Cancer Treat Rev, 1999;25:199-206.
19. Tormey DC, Weinberg VE, Leone LA, et al., A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study, Am J Clin Oncol, 1984;7:231-9.
20. Coates A, Gebski V, Bishop JF, et al., Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies, N Engl J Med, 1987;317:1490-5.
21. Muss HB, Case LD, Richards F, et al., Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association, N Engl J Med, 1991;325:1342-8.
22. French Epirubicin Study Group, Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment, J Clin Oncol, 2000;18:3115-24
23. Maughan TS, James RD, Kerr DJ, et al., Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial, Lancet, 2003;361:457-64.
24. Tournigand C, Cervantes A, Figer A, et al., OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study, J Clin Oncol, 2006;24:394-400.
25. Chibaudel B, Maindrault-Goebel F, Lledo G, et al., Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study, J Clin Oncol, 2009;27:5727-33.
26. Adams RA, Meade AM, Seymour MT, et al., Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet Oncol, 2011;12:642-53.
27. Abrahamsson PA, Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature, Eur Urol, 2010;57:49-59
28. Loblaw DA, Virgo KS, Nam R, et al., Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 2007;25:1596-605.
29. Mottet N, Bellmunt J, Bolla M, et al., EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 2011;59:572-83.
30. Caffo O, Lo RE G, Sava T, et al., Preliminary results of a factorial phase II randomized trial of continuous (c) or intermittent (i) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial), J Clin Oncol, 2012;30: Abstract #220.
31. Miller K, Steiner U, Machtens S, et al., Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone-refractory prostate cancer (HRPC): A multicenter phase II study [Abstract], Proc Am Soc Clin Oncol, 2003;22:Abstract #1660.
32. Miller K, Wülfing C, Lehmann J, et al., Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: Preliminary results of a multicenter Phase II study (AUO AP33/02) [abstract], J Clin Oncol, 2005;23:Abstract #4613.
33. Beer TM, Garzotto M, Henner WD, et al., Multiple cycles of intermittent chemotherapy in metastatic androgenindependent prostate cancer, Br J Cancer, 2004;91:1425-7.
34. Beer TM, Ryan CW, Venner PM, et al., Intermittent chemotherapy in patients with metastatic androgenindependent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel, Cancer, 2008;112:326-30.
35. Scher HI, Jia X, Chi K, et al., Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer, J Clin Oncol, 2011;29:2191-8.
36. Beer TM, Ryan CW, Venner PM, et al., Intermittent chemotherapy in patients with metastatic androgenindependent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel, Cancer, 2008;112:326-30.
37. Di Lorenzo G, Buonerba C, Faiella A, et al., Phase II study of docetaxel re-treatment in docetaxel-pretreated castrationresistant prostate cancer, BJU Int, 2011;107:234-9.
38. Harzstark A, Beer TM, Weinberg VK, et al., Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium [abstract], J Clin Oncol, 2011;29:Absract #133.
39. Ansari J, Hussain SA, Zarkar A, et al., Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience, Oncol Rep, 2008;20:891-6.
40. Soga N, Kato M, Nishikawa K, et al., Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients, Int J Clin Oncol, 2009;14:130-5.
41. Eymard JC, Oudard S, Gravis G, et al., Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study, BJU Int, 2010;106:974-8.
42. Loriot Y, Massard C, Gross-Goupil M, et al., The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer, Eur J Cancer, 2010;46:1770-2.
43. Caffo O, Pappagallo G, Brugnara S, et al., Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors, Urology, 2012 (in press).
44. Mountzios I, Bournakis E, Efstathiou E, et al., Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer, Urology, 2011;77:682-7.
45. Gernone A, Pagliarulo A, Calderoni G, et al., Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment [abstract], J Clin Oncol, 2011;29:Abstract #161.
46. Fuxius S, Mueller A, Kleitz K, et al., Weekly docetaxel rechallenge in patients with hormone-resistant prostate cancer refractory to conventionally three weekly docetaxel [abstract], J Clin Oncol, 2010;28:Abstract #e15004
47. Markman M, Rothman R, Hakes T, et al., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J Clin Oncol, 1991;9:389-93.
48. Sevcenco S, Kramer G, Klatte T, et al., Predictors of response to docetaxel re-treatment in patients with castration resistant prostate cancer [abstract], Eur Urol, 2010;9:Abstract #C156.
49. Jancovic B, Beardsley E, Chi KN, Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: A population based analysis [abstract #196], Proc ASCO Genitourinary Cancers Symposium, San Francisco, 2008
50. Heidenreich A, Pfister D, Thuer D, et al., Docetaxel rechallenge versus docetaxel/bevacizumabin castrationresistant prostate cancer following first-line docetaxel [abstract], J Clin Oncol, 2010;28:Absract #e15006.
51. Firek P, Pfister D, Thuer D, et al., Docetaxel rechallenge at PSA relapse after docetaxel chemotherapy at hormonerefractory prostate cancer [abstract #93], Proc 2010 ASCO Genitourinary Cancers Symposium, San Francisco, 2010.
52. Gernone A, Pagliarulo A, Pagliarulo V, Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC) [abstract], J Clin Oncol, 2010;28:Abstract e15020
53. Bracarda S, Sisani M, Rossi M, et al., Docetaxel rechallenge chemotherapy in metastatic castration resistant prostate cancer (mCRPC) [abstract], J Clin Oncol, 2011;29:Abstract #e15145.
54. Robert L, Maroto J, Sebio A, et al., Docetaxel rechallenge in patients with prostate cancer progressing under castration levels of testosterone (PPuCT): A single-center study (abstract), J Clin Oncol, 2011;29:Abstract #e15105.